Erdheim-Chester disease –⁠ the rare and under-diagnosed disease –⁠ editorial

Czech version

Authors: Martin Mistrík
Authors‘ workplace: Klinika hematológie a transfúziológie LF UK a UN, Nemocnica sv. Cyrila a Metoda Bratislava, Slovenská republika, prednosta doc. MUDr. Martin Mistrík, PhD.
Published in: Vnitř Lék 2014; 60(5-6): 410-411
Category: Editorial

Sources

1. Adam Z et al. PET-CT dokumentovaná kompletní remise Erdheimovy-Chesterovy nemoci, trvajíci již čtyři roky od zahájení léčby kladribinem. Popis případu a přehled informací o léčbě. Vnitř Lék 2014; 60(5–6): 499–511.

2. Mazor RD, Manevich-Mazor M, Shoenfeld Y Erheim. Chester Disease: a comprehensive review of the literature. Orphanet J Rare Dis 2013; 8 : 137. Dostupné z DOI: <http://doi: 10.1186/1750–1172–8-1373>.

3. Cavalli G, Guglielmi B, Berti A et al. The multifaceted clinical presentations and manifestations of Erdheim-Chester disease: comprehensive review of the literature and of 10 new cases. Ann Rheum Dis 2013; 72(19): 1691–1695.

4. Erdheim-Chester Disease Global Alliance. Dostupné z WWW: <http://www.erdheim-chester.org>.

5. Plank L. Diagnostická patológia non-Langerhansových histiocytóz. Vnitř Lék 2010; 56(Suppl 2): S39-S63.

6. Arnaud L, Hervier B, Néel A et al. CNS involvement and treatment with interferon-alfa are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients. Blood 2011; 117(10): 2778–2782.

7. Haroche J, Charlotte F, Arnaud L et al. High prevalence of BRAF V600E mutations in Erdheim Chester disease but not in other non-Langerhans cell histiocytoses. Blood 2012; 120(13): 2700–2703.

8. Haroche J, Cohen-Aubart F, Emile JF et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood 2013; 121(9): 1495–1500.